|
|
Volumn 9, Issue 2, 2004, Pages 144-146
|
|
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BCR ABL PROTEIN;
BIOLOGICAL MARKER;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEFITINIB;
IMATINIB;
PLATELET DERIVED GROWTH FACTOR RECEPTOR;
PROTEIN TYROSINE KINASE INHIBITOR;
RAF PROTEIN;
SORAFENIB;
STEM CELL FACTOR RECEPTOR;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
VASCULOTROPIN INHIBITOR;
VASCULOTROPIN RECEPTOR;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CANCER THERAPY;
CLINICAL TRIAL;
CONFERENCE PAPER;
DNA MICROARRAY;
DRUG EFFICACY;
DRUG POTENCY;
DRUG SAFETY;
DRUG SELECTIVITY;
DRUG TARGETING;
ENZYME INHIBITION;
GENE EXPRESSION PROFILING;
GENE TARGETING;
GENE TRANSFER;
HUMAN;
KIDNEY CARCINOMA;
MOLECULAR BIOLOGY;
PHARMACOGENOMICS;
SIGNAL TRANSDUCTION;
SOLID TUMOR;
DRUG DESIGN;
GENE THERAPY;
GENETICS;
METABOLISM;
NEOPLASM;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DRUG DESIGN;
GENE THERAPY;
HUMANS;
NEOPLASMS;
UNITED STATES;
|
|
EID: 1342290237
PISSN: 15250016
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ymthe.2004.01.001 Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (0)
|
